A Trial of Plerixafor With G-CSF as Additional Agents in Conditioning Regimen for Prevention of Graft Failure After Transplantation With TCR Alpha/Beta Grafts Depletion in Patients With Wiskott-Aldrich Syndrome.
Phase of Trial: Phase II
Latest Information Update: 18 Jan 2017
At a glance
- Drugs Granulocyte colony-stimulating factors (Primary) ; Plerixafor (Primary)
- Indications Transplant rejection; Wiskott-Aldrich syndrome
- Focus Therapeutic Use
- 18 Jan 2017 New trial record